ELANCO UK AH LIMITED
Operating as a UK subsidiary of the New York Stock Exchange-listed Elanco Animal Health Incorporated, the company distributes veterinary pharmaceuticals and health products for farm animals and pets.
Get an alert when ELANCO UK AH LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£76m
+115.2% highest in 3 filed years
Net assets
£132m
+9.2% highest in 3 filed years
Employees
547
+65.3% highest in 3 filed years
Profit before tax
£16m
+73.7% highest in 3 filed years
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £331,449,000 | £342,988,000 | £322,738,000 | -5.9% | |
| Operating profit | £16,740,000 | £11,798,000 | £15,200,000 | +28.8% | |
| Profit before tax | £13,535,000 | £9,195,000 | £15,972,000 | +73.7% | |
| Net profit | £9,598,000 | £5,582,000 | £11,015,000 | +97.3% | |
| Cash | £21,691,000 | £35,097,000 | £75,537,000 | +115.2% | |
| Total assets less current liabilities | £114,933,000 | £122,240,000 | £132,639,000 | +8.5% | |
| Net assets | £114,005,000 | £120,699,000 | £131,777,000 | +9.2% | |
| Equity | £114,005,000 | £120,699,000 | £131,777,000 | +9.2% | |
| Average employees | 272 | 331 | 547 | +65.3% | |
| Wages | £22,621,000 | £28,298,000 | £44,302,000 | +56.6% | |
| Directors' remuneration | £557,000 | £580,000 | £830,000 | +43.1% | |
| Directors' pension contributions | £57,000 | £61,000 | £85,000 | +39.3% | |
| Highest paid director | £220,000 | £225,000 | £245,000 | +8.9% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 5.1% | 3.4% | 4.7% | |
| Net margin | 2.9% | 1.6% | 3.4% | |
| Return on capital employed | 14.6% | 9.7% | 11.5% | |
| Gearing (liabilities / total assets) | 50.9% | 44.1% | 36.7% | |
| Current ratio | 1.55x | 1.89x | 2.23x | |
| Interest cover | 3.80x | 3.31x | 15.82x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“On the basis of their assessment of the company's financial position, the Company's Directors have a reasonable expectation that the company will be able to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis of accounting”
Group structure
- ELANCO UK AH LIMITED · parent
- Dista Products Limited 100%
- Elanco Europe Limited 100%
- Vericore Limited 100%
- Elanco Animal Health UK Limited 100%
- Elanco Animal Vaccines Limited 100%
Significant events
- “In Q2, 2026 Elanco globally completed the acquisition of AHV International, a Dutch firm which brings a portfolio of products in the dairy sector... Elanco UK acquired the AHV UK trade and assets for approximately £0.5m.”
- “The Company's Speke manufacturing site, which was re-acquired in November 2024, was successfully integrated into Elanco's SAP operating systems on 1 May 2025.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BULL, Matthew Stephen William | Director | 2026-07-01 | Oct 1984 | British |
| DAVIS, Nicholas | Director | 2025-04-01 | Jun 1975 | British |
| FROST, Matthew Jonathan | Director | 2021-07-01 | Jul 1972 | British |
| LEWIS, Christopher | Director | 2018-06-20 | Aug 1978 | British |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| AMBANI, Nilesh (Neel) Sukumar | Director | 2018-05-23 | 2018-12-07 |
| HUNT, Kristina Mary | Director | 2018-12-07 | 2026-01-23 |
| TROUTT, Peter | Director | 2018-06-20 | 2021-12-03 |
| VANHERSECKE, Francois Jean-Noel Emile | Director | 2019-09-05 | 2021-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Elanco Europe Gmbh | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors, Significant influence (as firm) | 2019-03-11 | Ceased 2019-03-11 |
| Elanco Animal Health Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-03-11 | Active |
| Eli Lilly And Company Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-05-23 | Ceased 2019-03-11 |
Filing timeline
Last 20 of 51 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-09-08 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-15 | AA | accounts | Accounts with accounts type full | |
| 2026-09-08 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2026-09-08 | SH20 | capital | Legacy | |
| 2026-09-08 | CAP-SS | insolvency | Legacy | |
| 2026-09-08 | RESOLUTIONS | resolution | Resolution | |
| 2026-07-14 | AP01 | officers | Appoint person director company with name date | |
| 2026-06-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-06-05 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2026-01-29 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-07 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-08-21 | AA | accounts | Accounts with accounts type full | |
| 2025-06-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-05-22 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-18 | MR05 | mortgage | Mortgage charge part release with charge number | |
| 2024-09-10 | AA | accounts | Accounts with accounts type full | |
| 2024-07-23 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-06-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-09 | AA | accounts | Accounts with accounts type full | |
| 2023-09-20 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-09-20 | PSC07 | persons-with-significant-control | Cessation of a person with significant control |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 10
- Capital events
- 2
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.